Hassane Zarour
Basic Co-Leader · UPMC Medical Education
Credentials: · ·
History
- Present
- 1994–1997
Hematology and Medical Oncology
- 1991–1994
Internal Medicine
- 1987–1991
Doctor of Medicine
Research
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
New England Journal of Medicine · 2013 · 2,799 citations
The Lancet · 2014 · 1,497 citations
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients
Science · 2021 · 1,389 citations
39 papers
25 papers
- YN
12 papers
- JL
10 papers
8 papers
- AT
7 papers
7 papers
- JW
7 papers
Grants
- 2021–2027
Melanoma and Skin Cancer Program SPORE
National Cancer Institute · P50
Contact PI · $10.4M · University of Pittsburgh at Pittsburgh
- 2022–2027
Therapy with Fecal Microbiota Transplantation and Immune Checkpoint Blockade for Solid Tumors
National Cancer Institute · U01
Contact PI · $2.4M · University of Pittsburgh at Pittsburgh
- 2021–2027
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma
National Cancer Institute · R01
Contact PI · $2.6M · University of Pittsburgh at Pittsburgh
- 2018–2024
Fecal Microbiota Transplant and PD-1 Blockade in Melanoma
National Cancer Institute · R01
Contact PI · $2.5M · University of Pittsburgh at Pittsburgh
Clinical trials
- 2024–2030
Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors
Principal investigator · Recruiting
University of Pittsburgh
- 2014–2020
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Principal investigator · Completed · Phase 1
Hassane M. Zarour, MD
- 2014–2016
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Principal investigator · Terminated · Phase 1
Ludwig Institute for Cancer Research
- 2009–2015
Principal investigator · Completed · Phase 1
Hassane M. Zarour, MD